Precision BioSciences has filed for an initial public offering to continue its development of gene-edited cell therapies, including a cancer treatment that is set to start tests in humans in the coming months. The company is also forging ahead in gene therapy and agricultural applications, giving it breadth that sets it apart from others in […]
Original Article: Precision Bio Preps IPO to Test “Off-the-Shelf” Cancer Cell Therapy